Sanofi: Libtayo approved by EU
(CercleFinance.com) - Sanofi announces that Libtayo (cemiplimab) has been approved by the European Union for the treatment of advanced cutaneous squamous cell carcinoma.
Libtayo is the only drug approved in the EU for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (SCC) in patients who are not candidates for curative treatment or radiotherapy.
"CSCC is one of the most common skin cancers worldwide and is especially difficult to treat in advanced stages," the group said.
The updated data from the EMPOWER-CSCC-1 trial for registration was recently presented at the 2019 Congress of the American Society of Clinical Oncology.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Libtayo is the only drug approved in the EU for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (SCC) in patients who are not candidates for curative treatment or radiotherapy.
"CSCC is one of the most common skin cancers worldwide and is especially difficult to treat in advanced stages," the group said.
The updated data from the EMPOWER-CSCC-1 trial for registration was recently presented at the 2019 Congress of the American Society of Clinical Oncology.
Copyright (c) 2019 CercleFinance.com. All rights reserved.